Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone effects on ERN in Schizotypal Personality Disorder
NCT02535156Phase 2Completed
- Sponsor
- Hospital de la Santa Creu i Sant Pau Research Institute
- Start
- Jan 2003
- Primary completion
- Jan 2014
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of risperidone in schizotypal personality disorder (STPD) (2 arms), sponsored by Hospital de la Santa Creu i Sant Pau Research Institute. Primary endpoint: Error Related Negativity amplitude. Started Jan 2003; status: completed.
02
Drugs
risperidone
03
Conditions
schizotypal personality disorder (STPD)
Beyond the preview
Go deeper on NCT02535156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02535156.